Ukukhululwa Ngokweqile Kusho ukuthini Nge-Leukemi neLymphomas?
Incazelo: Ukuphendula okuyingxenye (PR)
Ngemuva kokuba kuqedwe ukwelashwa, umuntu ngokuvamile uhlolwe ukuphendula emva kwesikhathi sokuvumela ukucindezeleka okuphezulu kwe-tumor. Ekupheleni kwalesi sikhathi uma kukhona isifo esisele kodwa ukunciphisa izifo ngo-30% noma ngaphezulu ekuhlolweni kwekliniki noma x-ray kanye nezilinganiso - kuthiwa ukuphendula okuyingxenye (noma ukulungiswa okuyingxenye).
Kusho Ukuthini Ukuphendula Ngokukhetha?
Ukusabela okuyingxenye (PR) kusho ukuthi ukwelashwa okuqhubekayo kuyodingeka ukuthi uzame ukwelashwa. Kwezinye izicubu ezikhula kancane (kufaka phakathi i-low grade lymphomas ) akukho ukwelashwa okuqhubekayo okungadingeka ngokushesha kuze kube yilapho lesi sifo siqala ukukhula ngesayizi futhi.
Ukuqonda Imigomo Ukuchaza Ukwelashwa Kwemdlavuza
Kunamagama amaningi kakhulu asetshenziselwa ukuchaza ukwelashwa komdlavuza ukuthi udideka kakhulu. Ngenhlanhla eziningi zazo zisho ngento efanayo. Ezinye zazo zihlanganisa:
- Impendulo ephelele - Lokhu kusho ukuthi umdlavuza uphendule ukwelashwa futhi akukho bufakazi bomdlavuza obonakalayo ekufundiseni izithombe.
- Ukuqedela okuphelele - Lokhu kusho izinto ezifanayo njengempendulo ephelele.
- Ukusabela okuyingxenye - Kuchazwe ngenhla
- Ukukhululwa okuyingxenye kusho izinto ezifanayo njengokuphendula okuyingxenye
- I-NED (Ayikho ubufakazi besifo) kusho ukuthi ncamashi, futhi ingafana nokuphendula okuphelele noma ukuxolelwa okuphelele. Ucwaningo lokucwaninga "luvamile" kodwa lokho akusho ukuthi umdlavuza usukile, nje kuphela ukuthi akukho bufakazi obungatholakala emiphumeleni yokucabangela esinawo okwamanje.
- Izifo eziqhubekayo - Igama eliqhubekayo lesifo, noma i-PD, lisho ukuthi umdlavuza usukhulile (noma usakazeka) okungenani u-20%
- Isifo esiqinile - Lokhu kusho ukuthi isisu asizange sishintshe. Isifo esiqinile singasasho ukuthi umdlavuza usabele, isibonelo, uma umdlavuza ngabe kulindeleke ukuba uhambe kakhulu kodwa uhlale ufana.
- Ukuphindaphindiwe - Lokhu kusho ukuthi umdlavuza ubuye wabuya emva kwesikhathi sokulahlwa noma kuba yi-NED.
- Ukubuyela emuva - Lokhu kusho into efanayo nokuphindaphindiwe.
Uhlela emva kokuphendula okuyingxenye
Njengoba kuphawuliwe ngenhla, kwenzekani ngemuva kokuphendula okuyingxenye kuxhomeke kakhulu kulohlobo lomdlavuza onayo. Ngesizathu esifanayo, ukuphendula okuyingxenye kungase kube kuhle kakhulu noma kubi kakhulu - konke akuxhomekile kumdlavuza wakho othize, kodwa kumaphrofayli omzimba womdlavuza wakho othize. Uma ufuna ulwazi ngomdlavuza wakho gcina lokhu engqondweni. Izinombolo kanye nezibalo ku-inthanethi azicabangi ukuhlukahluka okukhulu phakathi kwabantu, ngisho nalabo abanomdlavuza ofanayo. Ngaphezu kwalokho, lokho okufundayo ku-intanethi kuzovame ukubhekisela kuzibalo. Izibalo zizinombolo hhayi abantu futhi ziyizilinganiso. Abantu abambalwa kakhulu "bangaphakathi." Futhi izibalo zihlanganiswa ndawonye ngokusebenzisa idatha evela kubantu abanomdlavuza wakho okwenzekile esikhathini esedlule ukwelashwa. Lezi zinombolo azicabangi noma yiluphi uhlobo lwezokwelapha ezintsha kusukela ngesikhathi idatha irekhodiwe, ngakho-ke angeke afaneleke kuwe.
Ukuphindaphinda kwe-Leukemia noma i-Lymphoma
Sikhuluma ngokuphendula okuyingxenye, kodwa ngemuva kwezingqondo zethu eziningi ukwesaba ukuphindaphindiwe.
Ungabhekana kanjani nokwesaba ukuphindaphinda noma ukwesaba ukuqhubekela phambili ? Kwenzekani lapho i-leukemia noma i-lymphoma ephindayo? Abantu abaningi bakuthola kuwusizo ukukhuluma ngendlovu egumbini - vula uphinde uveze lezi zimo. Ngezinye izikhathi ukukhuluma nomeluleki kuyasiza uma uzibamba uzikhathazayo. Siyajabula ukuthi siphila ngesikhathi lapho ama-cancer amaningi eqhubeka khona okusinda, futhi ukwelashwa okusha kuvunyelwe ngokushesha kunanini ngaphambili. Izivivinyo zemitholampilo ziyaqhubeka hhayi nje kuphela zokwelashwa esithemba ukuthi kuzokwenza ngcono ukusinda, kodwa zokwelapha ezinemiphumela emibi kakhulu kunangaphambili.
Futhi ubizwa ngokuthi: PR
Imithombo:
I-National Cancer Institute. Ukucabanga Impendulo Yokuphendula. Kufinyelele ngo 02/26/16. http://imaging.cancer.gov/clinicaltrials/imaging